Cargando…
Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy
PD-1/PD-L1 blockade therapy that eliminates T-cell inhibition signals is successful, but poor benefits are often observed. Increasing T-cell infiltration and quantity of PD-1/PD-L1 inhibitors in tumor can improve efficacy but remains challenging. Here, we devise tumor-specific gene nanomedicines to...
Autores principales: | Wang, Yue, Zhou, Shi-Kun, Wang, Yan, Lu, Zi-Dong, Zhang, Yue, Xu, Cong-Fei, Wang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082825/ https://www.ncbi.nlm.nih.gov/pubmed/37031188 http://dx.doi.org/10.1038/s41467-023-37656-w |
Ejemplares similares
-
Engineering Prodrug Nanomedicine for Cancer Immunotherapy
por: Yang, Bin, et al.
Publicado: (2020) -
Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
por: Peng, Shaojun, et al.
Publicado: (2021) -
Enhancing Combined Immunotherapy and Radiotherapy
through Nanomedicine
por: Hagan, C. Tilden, et al.
Publicado: (2020) -
Tumor microenvironment-responsive DNA-based nanomedicine triggers innate sensing for enhanced immunotherapy
por: Li, Jinyang, et al.
Publicado: (2023) -
Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy
por: Zhu, Yuefei, et al.
Publicado: (2020)